Interim report Q1 2021 Revenues amounted to MSEK 713.0 (793.6), corresponding to a decrease of -10% for the period. Revenues amounted to MSEK 713.0 ( 793.6), corresponding to a decrease of -10% for the period. The organic growth* during the first quarter was -16%. The currency impact in the quarter was -1% while the acquisitions of the product portfolios Proct from Leo Pharma and Pevaryl from Johnson & Johnson generated growth of +7%. EBIT (Operating Profit) amounted to MSEK 128.1 (104.1), corresponding to growth of 23%. EBITDA* amounted to MSEK 259.8 (209.3) corresponding to growth of 24%. The gross margin, defined as gross profit divided by revenues, was 60.9% (53.9%) for the quarter. The margin was affected positively by the acquired product portfolios, the divested Hospital Supply business and by realized synergies in production and distribution of products.